TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03425643
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1000 mg/m\^2 by IV infusion Q3W, given on cycle days 1 and 8. Given only to participants with squamous NSCLC.
Study: NCT03425643
Drug: Pemetrexed
Normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 500 mg/m\^2 by IV infusion Q3W, given on cycle day 1. Given only to participants with nonsquamous NSCLC.
Study: NCT01327573
Drug: eculizumab
Normalized name: Eculizumab
DrugBank: Eculizumab (DB01257)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: * Eculizumab Induction 600mg IV every 7 days for 4 doses~* Eculizumab 900mg IV 7 days later~* Eculizumab Maintenance 900mg IV every 14 days for total of 26 weeks
Study: NCT02916901
Drug: CKD-519 200mg
Normalized name: CKD-504
DrugBank: CKD-504 (DB18235)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00452868
Drug: Donepezil
Normalized name: Donepezil
DrugBank: Donepezil (DB00843)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Donepezil 5 milligrams a day for 6 weeks
Study: NCT04613271
Drug: Favipiravir
Normalized name: favipiravir
DrugBank: Favipiravir (DB12466)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Assignment of Administration Group 1:~Favipiravir 1600 mg twice a day at day 1 and 600 mg twice a day at day 7-14 + Azithromycin 500 mg once a day for 5 days.
Study: NCT01407406
Drug: BIIB023 - low dose IV Dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02309008
Drug: PAC-14028
Normalized name: PAC-14028
DrugBank: PAC-14028 (DB12428)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive PAC-14028 cream applied topically once a day for 9 days
Study: NCT01920945
Drug: OnabotulinumtoxinA
Normalized name: Onabotulinumtoxina
DrugBank: Botulinum toxin type A (DB00083)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: 155 units of OnabotulinumtoxinA, will be injected into 31 sites in the head and neck every 12 weeks for a total of 24 weeks using a sterile 30-gauge, 0.5 inch needle as 0.1 mL (5 Units) injections per each site. Injections will be divided across seven specific head/neck muscle areas (corrugator, procerus, frontalis, temporalis, suboccipital, splenius capitus and medial/lateral occipital, and trapezius).
Study: NCT01464125
Drug: Fosmidomycin
Normalized name: Fosmidomycin
DrugBank: Fosmidomycin (DB02948)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fosmidomycin sodium capsules 450 mg x 4 twelve-hourly for three days
Study: NCT01732276
Drug: gefitinib
Normalized name: Gefitinib
DrugBank: Gefitinib (DB00317)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02502162
Drug: LDN
Normalized name: LDN-193189
DrugBank: LDN-193189 (DB18051)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04376970
Drug: Cyclosporine A eye drops 0.5%
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The same regimen was prescribed for both treatments in order to preserve the double-blind characteristic. Cyclosporine eye drops 0.5%, was prepared from an oral solution of cyclosporine (Sandimmun®) and combined with castor oil, both sterilized by filtration. The preparation was carried out in a pharmacotechnical laboratory where a controlled atmosphere area was dedicated to ophthalmic preparations. The castor oil-Sandimmun® solution mixture is made in a sterile receptacle. After stirring, the mixture is distributed into sterile low density polyethylene bottles. A sterile insert and cap including a tamper-evident seal were placed on each bottle. A content control was then carried out on each batch produced. A sterility test was done on a batch of each day of preparation. Each bottle of each batch is then cleaned, polished, labeled and then packaged in a pre-printed box with an adapted notice. The stability was fixed at 6 months before opening and at 15 days after opening.
Study: NCT00899600
Drug: Ketamine
Normalized name: Ketamine
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Peripheral provision of 0.5mg/kg of ketamine on induction followed by a 10mcg/kg/min infusion until surgical wound closure
Study: NCT00033059
Drug: Tolcapone
Normalized name: Tolcapone
DrugBank: Tolcapone (DB00323)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01552863
Drug: Oxycodone
Normalized name: Oxycodone
DrugBank: Oxycodone (DB00497)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: One capsule of 40 mg PF-00345439 Formulation A, single dose
Study: NCT01552863
Drug: Oxycodone
Normalized name: Oxycodone
DrugBank: Oxycodone (DB00497)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: One capsule of 40 mg PF-00345439 Formulation E, single dose
Study: NCT01552863
Drug: Oxycodone
Normalized name: Oxycodone
DrugBank: Oxycodone (DB00497)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: One capsule of 40 mg PF-00345439 Formulation F, single dose
Study: NCT01552863
Drug: Oxycodone
Normalized name: Oxycodone
DrugBank: Oxycodone (DB00497)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: One capsule of 40 mg PF-00345439 Formulation G, single dose
Study: NCT01552863
Drug: Oxycodone
Normalized name: Oxycodone
DrugBank: Oxycodone (DB00497)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: One capsule of 5 mg PF-00345439 Formulation TBD, single dose
Study: NCT01552863
Drug: Oxycodone
Normalized name: Oxycodone
DrugBank: Oxycodone (DB00497)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: One capsule of 40 mg PF-00345439 Formulation H, single dose
Study: NCT03793361
Drug: Regorafenib
Normalized name: Regorafenib
DrugBank: Regorafenib (DB08896)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Oral Drug in the form of 40 mg tablets - Regorafenib (120 mg/d) once daily for 3 weeks on / 1 week off plus Best Supportive Care (BSC) until progression (according to RECIST 1.1), intolerance or consent withdrawal.~Provided by BAYER
Study: NCT00003967
Drug: etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00003967
Drug: topotecan hydrochloride
Normalized name: Topotecan Hydrochloride
DrugBank: Topotecan (DB01030)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02549001
Drug: amorolfine 5%
DrugBank: Amorolfine (DB09056)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00174928
Drug: Lansoprazole
Normalized name: Lansoprazole
DrugBank: Lansoprazole (DB00448)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lansoprazole 0.5 mg/kg/day suspension, orally, once daily for up to 5 days.
Study: NCT00174928
Drug: Lansoprazole
Normalized name: Lansoprazole
DrugBank: Lansoprazole (DB00448)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lansoprazole 1.0 mg/kg/day suspension, orally, once daily for up to 5 days.
Study: NCT01010971
Drug: Ciclesonide HFA 160 μg
DrugBank: Ciclesonide (DB01410)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ciclesonide HFA Nasal Aerosol 160 μg once daily
Study: NCT02164604
Drug: intravitreal injection of 0.03ml ranibizumab
DrugBank: Ranibizumab (DB01270)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT01010971
Drug: Ciclesonide HFA 80 μg
DrugBank: Ciclesonide (DB01410)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ciclesonide HFA Nasal Aerosol 80 μg once daily
Study: NCT02515188
Drug: Propacetamol
Normalized name: Propacetamol
DrugBank: Propacetamol (DB09288)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Randomly selected patients of the propacetamol group are given intravenous propacetamol 2g for 15 minutes on the beginning of the procedure.
Study: NCT01835158
Drug: Cabozantinib S-malate
Normalized name: Cabozantinib S-Malate
DrugBank: Cabozantinib (DB08875)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given PO
Study: NCT01835158
Drug: Sunitinib Malate
Normalized name: Sunitinib Malate
DrugBank: Sunitinib (DB01268)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Given PO
Study: NCT01922141
Drug: Aliskiren
Normalized name: Aliskiren
DrugBank: Aliskiren (DB09026)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aliskiren 150 mg and aliskiren 300 mg tablets will be supplied centrally. These will be blinded with matching placebos for the 2 dose strengths.
Study: NCT01922141
Drug: Amlodipine
Normalized name: Amlodipine
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amlodipine 5 mg/10 mg will also be blinded and supplied centrally. For Aliskiren dual therapy arm , Amlodipine is in the regimen; where as for monotherapy arms, Amlodipine is an optional add-on therapy.
Study: NCT01922141
Drug: Ramipril
Normalized name: Ramipril
DrugBank: Ramipril (DB00178)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ramipril 5 mg and ramipril 10 mg capsules will be supplied centrally. These will be blinded with matching placebos for the 2 dose strengths.
Study: NCT01922141
Drug: Hydrochlorothiazide
Normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydrochlorothiazide 12.5 mg/25 mg will be open label and supplied locally. It is an optional add-on to each arm.
Study: NCT00653588
Drug: Atorvastatin
Normalized name: Atorvastatin
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 80mg
Study: NCT04661007
Drug: tafasitamab
Normalized name: Tafasitamab
DrugBank: Tafasitamab (DB15044)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: tafasitamab will be administered at protocol defined timepoints based on the groups participants are assigned.
Study: NCT04661007
Drug: lenalidomide
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: lenalidomide will be administered orally at protocol defined timepoints based on the groups participants are assigned.
Study: NCT04661007
Drug: parsaclisib
Normalized name: Parsaclisib
DrugBank: Parsaclisib (DB14867)
Approvals — FDA: no, EMA: no, PMDA: no
Description: parsaclisib will be administered at protocol defined timepoints based on the groups participants are assigned.
Study: NCT01383161
Drug: Curcumin
Normalized name: Curcumin
DrugBank: Curcumin (DB11672)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Six Theracurmin capsules (containing 30 mg of curcumin each) per day for 18 months.
Study: NCT01399190
Drug: Oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine administered according to prescribing information and normal clinical practice.
Study: NCT00963833
Drug: Interferon beta-1b (Betaseron, BAY86-5046)
Normalized name: Interferon Beta-1B
DrugBank: Interferon beta-1b (DB00068)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients under daily life treatment receiving Betaferon according to local product information.
Study: NCT02715804
Drug: nab-Paclitaxel
Normalized name: NAB-PACLITAXEL COMPONENT PACLITAXEL
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Nab-paclitaxel will be administered as per the dose and schedule specified in the respective arms.
Study: NCT02715804
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Gemcitabine will be administered as per the dose and schedule specified in the respective arms.
Study: NCT00205946
Drug: Bupropion
Normalized name: Bupropion
DrugBank: Bupropion (DB01156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 150 mg of bupropion administered 5 hours before fMRI scanning
Study: NCT00626834
Drug: Vigabatrin
Normalized name: Vigabatrin
DrugBank: Vigabatrin (DB01080)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dose 1 BID
Study: NCT00626834
Drug: Vigabatrin
Normalized name: Vigabatrin
DrugBank: Vigabatrin (DB01080)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dose 2 BID
Study: NCT00626834
Drug: Vigabatrin
Normalized name: Vigabatrin
DrugBank: Vigabatrin (DB01080)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dose 3 BID
Study: NCT02550119
Drug: Aprepitant
Normalized name: Aprepitant
DrugBank: Aprepitant (DB00673)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT02550119
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given PO or IV
Study: NCT02550119
Drug: Dolasetron Mesylate
Normalized name: Dolasetron Mesylate
DrugBank: Dolasetron (DB00757)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO or IV
Study: NCT04431141
Drug: Teneligliptin
Normalized name: teneligliptin
DrugBank: Teneligliptin (DB11950)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Teneligliptin alone
Study: NCT04431141
Drug: Empagliflozin
Normalized name: Empagliflozin
DrugBank: Empagliflozin (DB09038)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Empagliflozin alone
Study: NCT04431141
Drug: Teneligliptin and Empagliflozin
Normalized name: linagliptin and empagliflozin
DrugBank: Empagliflozin (DB09038)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Teneligliptin and empagliflozin
Study: NCT04673240
Drug: Botulinum toxin type A injection
Normalized name: botulinum toxin type A Injection
DrugBank: Botulinum toxin type A (DB00083)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: Adult patients with spasticity due to traumatic brain injury, spinal cord injury, or MS, treated with Botulinum Toxin type A.~As this is a non-interventional study, no diagnostic, therapeutic, or experimental intervention is involved. Subjects will receive clinical assessments, medications, and treatments solely as determined by their study physician.
Study: NCT02586727
Drug: aflibercept
Normalized name: Aflibercept
DrugBank: Aflibercept (DB08885)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: This study will consist of 2 simultaneous treatment arms of aflibercept: A six week dosing regimen arm and a treat and extend (TAE) dosing regimen arm, total duration 54 weeks. In the TAE arm the patients will receive an intravitreal aflibercept injection first visit, again at the second visit at 6 weeks, and then begin treat and extend from second injection forward.
Study: NCT01651871
Drug: S-555739 Dose 1
Normalized name: menthol 1 MG [Luden's]
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01651871
Drug: S-555739 Dose 2
Normalized name: S-2
DrugBank: Racepinephrine (DB11124)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01651871
Drug: Cetirizine HCl Dose 1
Normalized name: Cetirizine Hydrochloride
DrugBank: Cetirizine (DB00341)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01651871
Drug: Cetirizine HCl placebo
DrugBank: Cetirizine (DB00341)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03939975
Drug: pembrolizumab or nivolumab or JS001
Normalized name: edaravone
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: ICIs therapy of nivolumab (3 mg/kg, per 2 weeks) or pembrolizumab (2 mg/kg, per 3 weeks) or JS001 (240mg, per 3 weeks) was performed until the off-treatment criteria were met. For participants with stable disease or atypical progression to ICIs therapy, thermal ablation of radiofrequency ablation or microwave ablation was performed addtionally.
Study: NCT03424044
Drug: XeriSol glucagon
Normalized name: Glucagon
DrugBank: Glucagon (DB00040)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: XeriSol glucagon is an investigational drug that is a stable, soluble liquid glucagon formulation that can be injected or administered through an insulin pump. XeriSol glucagon will be used to fill the Omnipod to deliver glucagon for the Artificial Pancreas Controller in Dual Hormone mode.
Study: NCT00907504
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin 80 mg/m2 every 3 weeks
Study: NCT00907504
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Gemcitabine 1,250 mg/m2 Day1+8 of evey 3 week-cycle
Study: NCT00731679
Drug: Rifaximin
Normalized name: Rifaximin
DrugBank: Rifaximin (DB01220)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01374633
Drug: 1: Sevoflurane
DrugBank: Sevoflurane (DB01236)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mean sevoflurane infusion rate will be around 6 ml/h or 72 ml for 12 hours. Maximal infusion rate will be around 12 ml/h, or 144 ml for 12 hours. Packaging: bottle containing 250 ml of liquid sevoflurane for evaporation. Administration mode: anaesthetic conserving device for volatile anaesthetics.
Study: NCT00531635
Drug: Mycophenolate Mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Induction of Mixed Hemopoietic Chimerism in Patients Using Mycophenolate Mofetil
Study: NCT00094835
Drug: Motesanib diphosphate
Normalized name: trisodium diphosphate
DrugBank: Motesanib (DB05575)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose-finding with an initial dose of 50 mg once daily and up to 125 mg once daily. 75 mg twice daily was also to be tested.
Study: NCT00094835
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel 200 mg/m\^2 administered by IV infusion over 3 hours.
Study: NCT00094835
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carboplatin was administered IV over approximately 30 minutes. Carboplatin was dosed using the glomerular filtration rate (GFR) and Calvert formula to AUC/time curve of 6 mg/mL×min.
Study: NCT02352844
Drug: Everolimus
Normalized name: Everolimus
DrugBank: Everolimus (DB01590)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00917761
Drug: Entecavir and peginterferon (Pegasys) (52 weeks)
Normalized name: Entecavir
DrugBank: Entecavir (DB00442)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Entecavir 0.5 mg/day po at week 1-4 Peginterferon alfa-2a 180 ug/week sc at week 5-52
Study: NCT00917761
Drug: Peginterferon (Pegasys) (96 weeks)
Normalized name: peginterferon alfa-2a Injection [Pegasys]
DrugBank: Peginterferon alfa-2a (DB00008)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Peginterferon alfa-2a 180 ug/week sc at week 1-96
Study: NCT00917761
Drug: Peginterferon (Pegasys) (48 weeks)
Normalized name: peginterferon alfa-2a Injection [Pegasys]
DrugBank: Peginterferon alfa-2a (DB00008)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Peginterferon alfa-2a 180 ug/week sc at week 1-48
Study: NCT00646425
Drug: Basiliximab
Normalized name: Basiliximab
DrugBank: Basiliximab (DB00074)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 40 mg basiliximab administered as short iv infusion once every 2 weeks for 3 doses and at Weeks 8 and 12 for a total of 5 doses
Study: NCT02683707
Drug: Lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Local Anesthetic
Study: NCT02683707
Drug: Midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: IV sedation
Study: NCT02444936
Drug: ZOSTAVAX
Normalized name: Zostavax
DrugBank: Varicella zoster vaccine (live/attenuated) (DB10318)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shingles vaccine
Study: NCT03542149
Drug: 480 mg Piperaquine phosphate
Normalized name: piperazine 50 MG/ML
DrugBank: Piperaquine (DB13941)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: 480 mg Piperaquine is a bis 4-aminoquinoline and was used mainly in China from the 1960's to the 1980's as an antimalarial monotherapy.
Study: NCT00566852
Drug: Memantine
Normalized name: Memantine
DrugBank: Memantine (DB01043)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients began taking memantine(by mouth) while receiving radiation therapy. Patients continued taking memantine for 24 weeks or until doctor thinks it is in their best interest to stop. They started with 5 mg once a day. After a week dose increased to 5 mg twice a day. At week 3, dose increased to 10 mg in the morning and 5 mg in the evening. Weeks 4-24, dose was 10 mg twice a day.
Study: NCT03542149
Drug: 640 mg Piperaquine phosphate
Normalized name: piperazine 50 MG/ML
DrugBank: Piperaquine (DB13941)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: 640 mg Piperaquine is a bis 4-aminoquinoline and was used mainly in China from the 1960's to the 1980's as an antimalarial monotherapy.
Study: NCT01147055
Drug: crizotinib
Normalized name: Crizotinib
DrugBank: Crizotinib (DB08865)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Treatment A: a single 250-mg dose of crizotinib will be administered in the fasted state on Day 1 as 1 × 50-mg and 2 × 100-mg Immediate Release Tablets.
Study: NCT03542149
Drug: 200 mg OZ 439
Normalized name: pyrantel pamoate 0.439 MG/MG [Exodus]
DrugBank: Pyrantel (DB11156)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg OZ439 + α-tocopherol polyethylene glycol 1000 succinate (TPGS) granules for oral suspension
Study: NCT03542149
Drug: 400 mg OZ 439
Normalized name: pyrantel pamoate 0.439 MG/MG [Exodus]
DrugBank: Pyrantel (DB11156)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg OZ439 + α-tocopherol polyethylene glycol 1000 succinate (TPGS) granules for oral suspension
Study: NCT03542149
Drug: 800 mg OZ 439
Normalized name: pyrantel pamoate 0.439 MG/MG [Exodus]
DrugBank: Pyrantel (DB11156)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800 mg OZ439 + α-tocopherol polyethylene glycol 1000 succinate (TPGS) granules for oral suspension
Study: NCT03542149
Drug: 960 mg PQP
Normalized name: pegvaliase-pqpz 20 MG/ML
DrugBank: Pegvaliase (DB12839)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 960 mg Piperaquine is a bis 4-aminoquinoline and was used mainly in China from the 1960's to the 1980's as an antimalarial monotherapy.
Study: NCT03542149
Drug: 320 mg PQP
Normalized name: pegvaliase-pqpz 20 MG/ML
DrugBank: Pegvaliase (DB12839)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 320 mg Piperaquine is a bis 4-aminoquinoline and was used mainly in China from the 1960's to the 1980's as an antimalarial monotherapy.
Study: NCT01789892
Drug: methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT01147055
Drug: rifampin
Normalized name: Rifampin
DrugBank: Rifampin (DB01045)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment B: 600 mg once a day doses of rifampin will be orally administered after overnight fasting from Day 1 to Day 14.
Study: NCT01147055
Drug: crizotinib
Normalized name: Crizotinib
DrugBank: Crizotinib (DB08865)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Treatment B: A single 250-mg dose of crizotinib will be administered in the fasted state on Day 9 as 1 × 50-mg and 2 × 100-mg Immediate Release Tablets.
Study: NCT01817439
Drug: Amiodarone
Normalized name: Amiodarone
DrugBank: Amiodarone (DB01118)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: patients will be randomly assigned to oral OR IV Amiodarone
Study: NCT02218762
Drug: Fluticasone Propionate/Salmeterol Xinafoate DISKUS
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: A blister strip contained within the DISKUS inhaler. Each blister contains a small quantity of powder comprising of a blend of fluticasone propionate (micronized)(100 mcg), salmeterol xinafoate (micronized) (50 mcg) and excipient(s). One blister to be administered twice daily via DISKUS inhaler
Study: NCT02218762
Drug: Fluticasone Propionate/Salmeterol Xinafoate ROTACAPS
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: A capsule containing a small quantity of powder comprising of a blend of fluticasone propionate (micronized) (100 mcg), salmeterol xinafoate (micronized) (50 mcg) and excipient(s). One capsule to be administered twice daily via ROTAHALER inhaler